TipRanks
Advertisement
Advertisement

DE:4DN Stock Latest News

Denali Therapeutics price target raised to $35 from $30 at B. Riley
The FlyDenali Therapeutics price target raised to $35 from $30 at B. Riley
27d ago
DNLI
Denali Therapeutics’ AVLAYAH Launch Reshapes Earnings Story
PremiumCompany Announcements
Denali Therapeutics’ AVLAYAH Launch Reshapes Earnings Story
1M ago
DNLI
Analyst Reiterates Buy on Denali Therapeutics as AVLAYAH Launch Gains Traction and Alzheimer’s Pipeline Advances; $42 Price Target Maintained
PremiumRatings
Analyst Reiterates Buy on Denali Therapeutics as AVLAYAH Launch Gains Traction and Alzheimer’s Pipeline Advances; $42 Price Target Maintained
2M ago
DNLI
Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley
PremiumThe Fly
Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley
2M ago
DNLI
Denali Therapeutics price target raised to $34 from $25 at UBS
PremiumThe Fly
Denali Therapeutics price target raised to $34 from $25 at UBS
2M ago
DNLI
Denali Therapeutics price target raised to $34 from $31 at Baird
PremiumThe FlyDenali Therapeutics price target raised to $34 from $31 at Baird
2M ago
DNLI
Denali Therapeutics reports Q2 EPS (68c), consensus (47c)
Premium
The Fly
Denali Therapeutics reports Q2 EPS (68c), consensus (47c)
2M ago
DNLI
Denali Therapeutics treatment of frontotemporal dementia granted orphan status
Premium
The Fly
Denali Therapeutics treatment of frontotemporal dementia granted orphan status
2M ago
DNLI
Denali Therapeutics Sells Priority Review Voucher for Capital
PremiumCompany Announcements
Denali Therapeutics Sells Priority Review Voucher for Capital
2M ago
8K
DNLI
Denali Therapeutics price target raised to $36 from $35 at Morgan Stanley
PremiumThe Fly
Denali Therapeutics price target raised to $36 from $35 at Morgan Stanley
2M ago
DNLI
Denali Therapeutics price target raised to $35 from $31 at Deutsche Bank
PremiumThe Fly
Denali Therapeutics price target raised to $35 from $31 at Deutsche Bank
2M ago
DNLI
Denali Therapeutics falls -14.1%
PremiumThe Fly
Denali Therapeutics falls -14.1%
2M ago
DNLI
Denali Therapeutics falls -12.4%
PremiumThe FlyDenali Therapeutics falls -12.4%
2M ago
DNLI
Denali Therapeutics price target raised to $26 from $20 at Wedbush
Premium
The Fly
Denali Therapeutics price target raised to $26 from $20 at Wedbush
2M ago
DNLI
Denali Therapeutics resumed with an Overweight at JPMorgan
Premium
The Fly
Denali Therapeutics resumed with an Overweight at JPMorgan
2M ago
DNLI
Denali Monetizes FDA Voucher to Advance CNS Pipeline
PremiumCompany Announcements
Denali Monetizes FDA Voucher to Advance CNS Pipeline
3M ago
8K
DNLI
Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV
PremiumThe Fly
Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV
3M ago
DNLI
Denali Therapeutics Shareholders Back Board, Auditors, Executive Pay
PremiumCompany Announcements
Denali Therapeutics Shareholders Back Board, Auditors, Executive Pay
4M ago
8K
DNLI
Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley
PremiumThe Fly
Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley
4M ago
DNLI
Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank
PremiumThe FlyDenali Therapeutics price target lowered to $31 from $35 at Deutsche Bank
4M ago
DNLI
Denali Therapeutics: Buy Rating Reiterated as TV Platform and Enzyme Portfolio Drive Long-Term Upside; $42 Price Target Maintained
Premium
Ratings
Denali Therapeutics: Buy Rating Reiterated as TV Platform and Enzyme Portfolio Drive Long-Term Upside; $42 Price Target Maintained
4M ago
DNLI
Denali, Biogen Halt Parkinson’s Trial After Efficacy Failure
Premium
Company Announcements
Denali, Biogen Halt Parkinson’s Trial After Efficacy Failure
4M ago
8K
DNLI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >